Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: A randomized controlled pilot trial (NCT00332254)

Osteoarthritis and Cartilage

Volumn 20, Issue 4, 2012, Pages 271-278

  Kraus, V B ^a   Birmingham, J ^a   Stabler, T V ^a   Feng, S ^a   Taylor, D C ^a   Moorman, C T ^a   Garrett, W E ^a   Toth, A P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anterior cruciate ligament; Biomarkers; Clinical trial; IL 1Ra; Joint injury; Post traumatic arthritis

Indexed keywords

HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANTERIOR CRUCIATE LIGAMENT INJURY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYNOVIAL FLUID; SYNOVITIS;

ACTIVITIES OF DAILY LIVING; ADULT; ANTERIOR CRUCIATE LIGAMENT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KNEE INJURIES; MAGNETIC RESONANCE IMAGING; MALE; PAIN; PILOT PROJECTS; QUALITY OF LIFE; RECOVERY OF FUNCTION; SYNOVIAL FLUID; TRAUMA SEVERITY INDICES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858619829     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.12.009     Document Type: Article

References (56)

1. Brown T.D., Johnston R.C., Saltzman C.L., Marsh J.L., Buckwalter J.A. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma 2006, 20:739-744.
2. Buckwalter J.A., Saltzman C., Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004, S6-S15.
3. Lohmander L.S., Englund P.M., Dahl L.L., Roos E.M. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007, 35:1756-1769.
4. Cibere J., Zhang H., Garnero P., Poole A.R., Lobanok T., Saxne T., et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380.
5. Ling S.M., Patel D.D., Garnero P., Zhan M., Vaduganathan M., Muller D., et al. Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage 2009, 17:43-48.
6. Lohmander L.S., Hoerrner L.A., Dahlberg L., Roos H., Bjornsson S., Lark M.W. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993, 20:1362-1368.
7. Lohmander L.S., Roos H., Dahlberg L., Hoerrner L.A., Lark M.W. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus. J Orthop Res 1994, 12:21-28.
8. Chaudhari A.M., Briant P.L., Bevill S.L., Koo S., Andriacchi T.P. Knee Kinematics, Cartilage Morphology, and Osteoarthritis after ACL Injury. Med Sci Sports Exerc 2008.
9. Frobell R.B., Roos E.M., Roos H.P., Ranstam J., Lohmander L.S. A randomized trial of treatment for acute anterior cruciate ligament tears. N Engl J Med 2010, 363:331-342.
10. Roosendaal G., Vianen M., van den Berg H., Lafeber F., Bijlsma J. Cartilage damage as a result of hemarthrosis in a human in vitro model. J Rheumatol 1997, 24:1350-1354.
11. Marks P.H., Donaldson M.L. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 2005, 21:1342-1347.
12. Calich A.L., Domiciano D.S., Fuller R. Osteoarthritis: can anti-cytokine therapy play a role in treatment?. Clin Rheumatol 2010, 29:451-455.
13. van den Berg W.B., Joosten L.A., van de Loo F.A. TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol 1999, 17:S105-S114.
14. Kim J.M., Jeong J.G., Ho S.H., Hahn W., Park E.J., Kim S., et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 2003, 10:1543-1550.
15. Smeets R.L., Joosten L.A., Arntz O.J., Bennink M.B., Takahashi N., Carlsen H., et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 2005, 52:2202-2211.
16. Solignac M. Biological markers of osteoarthritis: data from the ECHODIAH cohort. Presse Medicale 2004, 33:22. [French].
17. de Isla N.G., Yang J.W., Huselstein C., Muller S., Stoltz J.F. IL-1beta synthesis by chondrocyte analyzed by 3D microscopy and flow cytometry: effect of Rhein. Biorheology 2006, 43:595-601.
18. Makarov S.S., Olsen J.C., Johnston W.N., Anderle S.K., Brown R.R., Baldwin A.S., et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996, 93:402-406.
19. Shamji M.F., Betre H., Kraus V.B., Chen J., Chilkoti A., Pichika R., et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 2007, 56:3650-3661.
20. Shamji M.F., Betre H., Chen J., Kraus V., Chilkoti A., Setton L.A. Development of a thermally responsive drug depot for intra-articular delivery of interleukin-1 receptor antaonist to attenuate inflammatory events in osteoarthritis. Osteoarthritis Cartilage 2007, 15:C226-C227.
21. Caron J.P., Fernandes J.C., Martel-Pelletier J., Tardif G., Mineau F., Geng C., et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544.
22. Pelletier J.P., Caron J.P., Evans C., Robbins P.D., Georgescu H.I., Jovanovic D., et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019.
23. Fernandes J., Tardif G., Martel-Pelletier J., Lascau-Coman V., Dupuis M., Moldovan F., et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159-1169.
24. Frisbie D.D., Ghivizzani S.C., Robbins P.D., Evans C.H., McIlwraith C.W. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002, 9:12-20.
25. Goekoop R.J., Kloppenburg M., Kroon H.M., Frolich M., Huizinga T.W., Westendorp R.G., et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage 2010, 18:942-947.
26. Swellam M., Mahmoud M.S., Samy N., Gamal A.A. Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk. Dis Markers 2010, 28:299-305.
27. Attur M., Wang H.Y., Kraus V.B., Bukowski J.F., Aziz N., Krasnokutsky S., et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann Rheum Dis 2010, 69:856-861.
28. Nakki A., Kouhia S.T., Saarela J., Harilainen A., Tallroth K., Videman T., et al. Allelic variants of IL1R1 gene associate with severe hand osteoarthritis. BMC Med Genet 2010, 11:50.
29. Solovieva S., Kamarainen O.P., Hirvonen A., Hamalainen S., Laitala M., Vehmas T., et al. Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol 2009, 36:1977-1986.
30. Meulenbelt I., Bos S.D., Kloppenburg M., Lakenberg N., Houwing-Duistermaat J.J., Watt I., et al. Interleukin-1 gene cluster variants with innate cytokine production profiles and osteoarthritis in subjects from the Genetics, Osteoarthritis and Progression Study. Arthritis Rheum 2010, 62:1119-1126.
31. Moxley G., Meulenbelt I., Chapman K., van Diujn C.M., Slagboom P.E., Neale M.C., et al. Interleukin-1 region meta-analysis with osteoarthritis phenotypes. Osteoarthritis Cartilage 2010, 18:200-207.
32. Chevalier X., Giraudeau B., Conrozier T., Marliere J., Kiefer P., Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317-1323.
33. Chevalier X., Goupille P., Beaulieu A., Burch F., Conrozier T., Loeuille D., et al. Results from a double blind, placebo-conrolled, multicenter trial of a single intra-articular injection of Anakinra (Kineret) in patients with osteoarthritis of the knee. Arthritis Rheum 2005, 52:S507.
34. Goupille P., Mulleman D., Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther 2007, 9:110.
35. Bacconnier L., Jorgensen C., Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 2009, 68:1078-1079.
36. Bresnihan B., Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology 2003, 42(Suppl 2):ii22-ii28.
37. Ehrich E.W., Davies G.M., Watson D.J., Bolognese J.A., Seidenberg B.C., Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000, 27:2635-2641.
38. Roos E.M., Lohmander L.S. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 2003, 1:64.
39. Chevalier X., Goupille P., Beaulieu A.D., Burch F.X., Bensen W.G., Conrozier T., et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352.
40. Amgen. Kineret (anakinra) [summary of product information]. In, vol. 2100 2001:FDA Briefing Information.
41. Martel-Pelletier J., Pelletier J.P. Osteoarthritis: a single injection of anakinra for treating knee OA?. Nat Rev Rheumatol 2009, 5:363-364.
42. Shelbourne K.D., Wilckens J.H., Mollabashy A., DeCarlo M. Arthrofibrosis in acute anterior cruciate ligament reconstruction. The effect of timing of reconstruction and rehabilitation. American Journal of Sports Medicine 1991, 19:332-336.
43. Passler J.M., Schippinger G., Schweighofer F., Fellinger M., Seibert F.J. Complications in 283 cruciate ligament replacement operations with free patellar tendon transplantation. Modification by surgical technique and surgery timing. Unfallchirurgie 1995, 21:240-246.
44. Almekinders L.C., Moore T., Freedman D., Taft T.N. Post-operative problems following anterior cruciate ligament reconstruction. Knee Surgery, Sports Traumatology, Arthroscopy 1995, 3:78-82.
45. Mayr H.O., Weig T.G., Plitz W. Arthrofibrosis following ACL reconstruction-reasons and outcome. Arch Orthop Trauma Surg 2004, 124:518-522. Epub 2004 Aug 2003.
46. Marx R.G., Jones E.C., Angel M., Wickiewicz T.L., Warren R.F. Beliefs and attitudes of members of the American Academy of Orthopaedic Surgeons regarding the treatment of anterior cruciate ligament injury. Arthroscopy 2003, 19:762-770.
47. Lewthwaite J., Blake S., Thompson R.C., Hardingham T.E., Henderson B. Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. Ann Rheum Dis 1995, 54:591-596.
48. Haupt J.L., Frisbie D.D., McIlwraith C.W., Robbins P.D., Ghivizzani S., Evans C.H., et al. Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res 2005, 23:118-126.
49. Dayer J.M. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin Exp Rheumatol 2002, 20:S14-S20.
50. Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006, 74:371-403.
51. Mitroulis I., Skendros P., Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010, 21:157-163.
52. Evans C.H. Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs 2005, 19:355-362.
53. Evans C.H., Ghivizzani S.C., Herndon J.H., Robbins P.D. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg 2005, 13:230-242.
54. Wehling P., Moser C., Frisbie D., McIlwraith C.W., Kawcak C.E., Krauspe R., et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs 2007, 21:323-332.
55. Evans C.H., Robbins P.D., Ghivizzani S.C., Wasko M.C., Tomaino M.M., Kang R., et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 2005, 102:8698-8703.
56. Evans C.H., Gouze J.N., Gouze E., Robbins P.D., Ghivizzani S.C. Osteoarthritis gene therapy. [Review] [134 refs]. Gene Therapy 2004, 11:379-389.